Avista Therapeutics develops innovative gene therapies for retinal diseases, including rare ophthalmic conditions that significantly impact patients' quality of life. The company uses its computationally guided scAAVengr platform to generate and validate a toolkit of proprietary AAV vectors. These vectors are designed to target specific cell types using minimally invasive intravitreal delivery and reduced dosages. A quantitative, in vivo-based approach and extensive clinical ophthalmology expertise enable the rapid translation of new gene therapies to the clinic.